Clinical trials
Brain Neoplasms trials in Poland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
24 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10 |
| Active, not recruiting | 5 |
| Unknown status | 4 |
| Recruiting | 3 |
| Terminated | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 2 |
| Bristol-Myers Squibb | 2 |
| Medical University of Warsaw | 2 |
| Novartis Pharmaceuticals | 2 |
| AbbVie | 1 |
| Children's Memorial Health Institute, Poland | 1 |
| Copernicus Memorial Hospital | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Genzyme, a Sanofi Company | 1 |
| Guerbet | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Brain Neoplasms | 24 |
| Breast Neoplasms | 5 |
| Glioblastoma | 5 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Glioma | 3 |
| Neoplasms | 3 |
| Meningioma | 2 |
| Neuroblastoma | 2 |
| Neuroendocrine Tumors | 2 |
| Anxiety Disorders | 1 |
Trials
Showing 26 to 24 of 24. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.